Evidence map›Paper›PMID 40004167›Full record

ArticleInternational journal of molecular sciences2025

Effect of Fibroblast Growth Factor-2 on Melanocyte Proliferation in Tissue-Engineered Skin Substitutes.

Karel Ferland, Brice Magne, Henri De Koninck, Martin A Barbier, Danielle Larouche, Lucie Germain

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Karel FerlandThe Tissue Engineering Laboratory (LOEX), Université Laval's Research Center, Quebec, QC G1V 0A6, Canada.ORCID 0000-0003-0715-3854
Brice MagneThe Tissue Engineering Laboratory (LOEX), Université Laval's Research Center, Quebec, QC G1V 0A6, Canada.
Henri De KoninckThe Tissue Engineering Laboratory (LOEX), Université Laval's Research Center, Quebec, QC G1V 0A6, Canada.ORCID 0009-0008-5574-4177
Martin A BarbierThe Tissue Engineering Laboratory (LOEX), Université Laval's Research Center, Quebec, QC G1V 0A6, Canada.ORCID 0000-0002-4298-4234
Danielle LaroucheThe Tissue Engineering Laboratory (LOEX), Université Laval's Research Center, Quebec, QC G1V 0A6, Canada.
Lucie GermainThe Tissue Engineering Laboratory (LOEX), Université Laval's Research Center, Quebec, QC G1V 0A6, Canada.ORCID 0000-0001-8883-6491

Funding

Canada Research Chair (Tier 1) from CIHR Stem Cells and Tissue EngineeringCanadian Institutes of Health Research (CIHR) FDN-143213 and PJT-180441Fondation des Pompiers du Québec pour les Grands Brûlés (F.P.Q.G.B.) NAFonds de recherche du Québec - Santé (FRQS NA
6 · The paper itself

Abstract

Burn patients treated with tissue-engineered skin substitutes (TESs) often experience pigmentation irregularities, including hypopigmentation and pigmentation spots. These issues are thought to stem from the reduced presence of melanocytes through dilution during TES manufacturing. To address this, we hypothesized that supplementing epithelial cell cultures-primarily composed of keratinocytes but also containing melanocytes-with Fibroblast Growth Factor-2 (FGF-2), a known promoter of melanocyte proliferation, could enhance melanocyte growth. This would potentially increase their numbers in TESs and improve pigmentation outcomes. Our findings indicate that FGF-2, at an optimal dose of 0.2 nM, effectively maintains melanocyte numbers in 2D cultures and epithelial cell cultures through the first passage. Importantly, this treatment does not interfere with keratinocyte proliferation or differentiation, nor does it affect TES integrity. However, FGF-2 supplementation alone did not increase the proportion of melanocytes in epithelial cultures beyond the first passage or in TESs. In summary, while FGF-2 supports melanocyte growth in culture, its addition alone was insufficient to significantly improve TES pigmentation.

Indexed as

Fibroblast Growth Factor 2MelanocytesSkin, ArtificialTissue EngineeringCell DifferentiationCell ProliferationCells, CulturedHumansKeratinocytesFibroblast Growth Factor 2cell culturemelanocytesskintissue-engineered substitutetissue engineering

Identifiers

PMID40004167
PMCPMC11855325

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.